Goldman Sachs
June 5, 2026
Americas Healthcare Generic Pharmaceuticals
Sector ReportEquitiesHealth Care
The Supreme Court's ruling in favor of Hikma regarding Amarin's Vascepa patents clarifies the 'skinny label' pathway for generic manufacturers. This decision reduces legal risks for the generic sector and is viewed as a positive development for companies like AMRX, TEVA, and VTRS.
Key Takeaways
- 1.The US Supreme Court ruled unanimously in favor of Hikma regarding its generic 'skinny label' product, finding no induced infringement of Amarin's patents.
- 2.The ruling provides greater clarity and confidence for generic manufacturers using the 'skinny label' (Section viii) pathway.
Table of Contents
- Background
- Valuation and Risks
- Disclosure Appendix
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Paul ChoiMatt Dellatorre, Ph.D.Daniel Ni
Securities
AMRNTEVA
Themes
Generic Drug RegulationPatent Litigation
Regions
North AmericaUnited States